Cargando…
Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients
Angioplasty with drug-coated balloon (DCB) is an emerging and reliable method for the treatment of femoro-popliteal lesions. We report our experience with the Stellarex™ DCB in the first 50 patients. METHODS: From July 2015 to November 2017, 50 patients (41 M, 9F), medium age (64 ± 7.4 year) were su...
Autores principales: | , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Università di Salerno
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350779/ https://www.ncbi.nlm.nih.gov/pubmed/30713834 |
_version_ | 1783390501261541376 |
---|---|
author | Bracale, UM Di Filippo, M De Capua, A Vanni, L Narese, D Pecoraro, F Giribono, AM Bracale, R |
author_facet | Bracale, UM Di Filippo, M De Capua, A Vanni, L Narese, D Pecoraro, F Giribono, AM Bracale, R |
author_sort | Bracale, UM |
collection | PubMed |
description | Angioplasty with drug-coated balloon (DCB) is an emerging and reliable method for the treatment of femoro-popliteal lesions. We report our experience with the Stellarex™ DCB in the first 50 patients. METHODS: From July 2015 to November 2017, 50 patients (41 M, 9F), medium age (64 ± 7.4 year) were subject to 33 angioplasties (PTAs) for femoro-popliteal lesions with a paclitaxel-coated balloon (Stellarex™). Based upon clinical data sixteen patients had severe claudication (56% - Rutherford class 3); ten patients suffered from ischemic rest pain (34% - Rutherford class 4); and five presented minor tissue loss (10% - Rutherford class 5). 42% of patients showed femoro-popliteal lesion TASC-II B, and 58% presented lesions pertaining to TASC-II C. RESULTS: Immediate technical success was 100% without perioperative complications. Primary patency rate was 94% at twelve months. In three cases restenosis (6%) was detected within a year from procedure, and a further PTA DCB was performed with primary assisted patency rates of 100% at twelve months. Two patients underwent major lower limb amputation. Three patients died during follow-up and one patient was lost at follow-up. CONCLUSION: DCB angioplasty with Stellarex™ is a viable alternative to traditional endovascular procedures proving satisfactory primary patency rates at twelve months. Based on our experience, treatment with DCB is a first choice technique for non-complex de novo lesions of the femoro – popliteal tract. |
format | Online Article Text |
id | pubmed-6350779 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | Università di Salerno |
record_format | MEDLINE/PubMed |
spelling | pubmed-63507792019-02-01 Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients Bracale, UM Di Filippo, M De Capua, A Vanni, L Narese, D Pecoraro, F Giribono, AM Bracale, R Transl Med UniSa Articles Angioplasty with drug-coated balloon (DCB) is an emerging and reliable method for the treatment of femoro-popliteal lesions. We report our experience with the Stellarex™ DCB in the first 50 patients. METHODS: From July 2015 to November 2017, 50 patients (41 M, 9F), medium age (64 ± 7.4 year) were subject to 33 angioplasties (PTAs) for femoro-popliteal lesions with a paclitaxel-coated balloon (Stellarex™). Based upon clinical data sixteen patients had severe claudication (56% - Rutherford class 3); ten patients suffered from ischemic rest pain (34% - Rutherford class 4); and five presented minor tissue loss (10% - Rutherford class 5). 42% of patients showed femoro-popliteal lesion TASC-II B, and 58% presented lesions pertaining to TASC-II C. RESULTS: Immediate technical success was 100% without perioperative complications. Primary patency rate was 94% at twelve months. In three cases restenosis (6%) was detected within a year from procedure, and a further PTA DCB was performed with primary assisted patency rates of 100% at twelve months. Two patients underwent major lower limb amputation. Three patients died during follow-up and one patient was lost at follow-up. CONCLUSION: DCB angioplasty with Stellarex™ is a viable alternative to traditional endovascular procedures proving satisfactory primary patency rates at twelve months. Based on our experience, treatment with DCB is a first choice technique for non-complex de novo lesions of the femoro – popliteal tract. Università di Salerno 2019-01-20 /pmc/articles/PMC6350779/ /pubmed/30713834 Text en http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Articles Bracale, UM Di Filippo, M De Capua, A Vanni, L Narese, D Pecoraro, F Giribono, AM Bracale, R Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients |
title | Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients |
title_full | Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients |
title_fullStr | Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients |
title_full_unstemmed | Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients |
title_short | Treatment of de novo femoro-popliteal lesions with a new Drug Coated Balloon: early experience of a single Center in the first 50 patients |
title_sort | treatment of de novo femoro-popliteal lesions with a new drug coated balloon: early experience of a single center in the first 50 patients |
topic | Articles |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6350779/ https://www.ncbi.nlm.nih.gov/pubmed/30713834 |
work_keys_str_mv | AT bracaleum treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT difilippom treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT decapuaa treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT vannil treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT naresed treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT pecorarof treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT giribonoam treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients AT bracaler treatmentofdenovofemoropopliteallesionswithanewdrugcoatedballoonearlyexperienceofasinglecenterinthefirst50patients |